🦜 Multiple [TIAB] AND sclerosis [TIAB] AND therapy [TIAB] AND trial
@pubmed.ncbi.nlm.nih.gov.rss-feed.feed.id.1bkd3nt7c-bb2ox2p4gq17anukdwtgc2lcfjxpodg3qewx1czi.utm.content.1bkd3nt7c-bb2ox2p4gq17anukdwtgc2lcfjxpodg3qewx1czi.utm.medium.rss.ff.20260423180744.utm.source.rss-parrot-bot.v.2.19.0.post6.133c1fe@rss-parrot.net
I'm an automated parrot! I relay a website's RSS feed to the Fediverse. Every time a new post appears in the feed, I toot about it. Follow me to get all new posts in your Mastodon timeline!
Brought to you by the RSS Parrot.
---
Multiple [TIAB] AND sclerosis [TIAB] AND therapy [TIAB] AND trial: Latest results from PubMed
Your feed and you don't want it here? Just
e-mail the birb.
Therapeutic acute intermittent hypoxia alters supraspinal neural control of lower limb movement in multiple sclerosis
https://pubmed.ncbi.nlm.nih.gov/43060299/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI&fc=None&ff=20261120212449&v=2.20.1
Published: November 20, 2026 11:00
Acute intermittent hypoxia (AIH) therapy is a promising neurorehabilitative intervention with well- documented improvement in motor function in people with spinal cord injury. Its effect on lower-limb motor control in multiple sclerosis (MS), where walking…
Impact of Adding Fatigue-Focused Cognitive Behavior Therapy to Supervised Pilates-Based Core Stability Training on Balance and Walking in Patients with Multiple Sclerosis: A Randomized Controlled Trial
https://pubmed.ncbi.nlm.nih.gov/43061942/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI&fc=None&ff=20261120212449&v=2.20.1
Published: November 20, 2026 11:00
ObjectiveTo investigate the effectiveness of adding cognitive behavioral therapy to supervised Pilates-based core stability training on balance and walking parameters in patients with multiple sclerosis.DesignDouble-blinded randomized controlled…
CD19 CAR T cell therapy alters disease-associated immune signatures in multiple sclerosis
https://pubmed.ncbi.nlm.nih.gov/43057228/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI&fc=None&ff=20261120002329&v=2.20.1
Published: November 19, 2026 11:00
Multiple sclerosis (MS) is a chronic inflammatory central nervous system (CNS) disease. Although current immunotherapies control relapses, they have limited impact on progression, which might reflect incomplete access to or modulation of compartmentalized…
Non-pharmacological fatigue management strategies in neurodegenerative conditions: a scoping review
https://pubmed.ncbi.nlm.nih.gov/43041155/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI&fc=None&ff=20261117062139&v=2.20.1
Published: November 17, 2026 11:00
CONCLUSIONS: Non-pharmacological interventions for fatigue in neurodegenerative disease are most developed in multiple sclerosis, where structured exercise, cognitive behavioral therapy, and educational/self-management approaches show the most consistent…
Rituximab and Ocrelizumab in Multiple Sclerosis: Does Comparative Evidence Redefine Anti-CD20 Therapy?
https://pubmed.ncbi.nlm.nih.gov/43030366/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI&fc=None&ff=20261114061155&v=2.20.1
Published: November 14, 2026 11:00
B-cell depletion has transformed multiple sclerosis treatment, with rituximab and ocrelizumab providing highly effective CD20-directed therapy. This narrative review aims to critically compare these agents from the mechanistic, clinical, safety,…
Online mindfulness-based cognitive therapy for people with multiple sclerosis with mild-to-moderate depression- protocol for a type 1 hybrid effectiveness-implementation study
https://pubmed.ncbi.nlm.nih.gov/43024620/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI&fc=None&ff=20261113194818&v=2.20.1
Published: November 13, 2026 11:00
CONCLUSION: The results from this study will provide evidence regarding the effectiveness of online MBCT in PwMS with mild to moderate depression, recommendations for intervention tailoring and implementation. Findings will be disseminated through…
Oral glucocorticoids added to ILD-modifying therapy in systemic sclerosis-associated interstitial lung disease: a target trial emulation study from the EUSTAR database
https://pubmed.ncbi.nlm.nih.gov/43015978/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI&fc=None&ff=20261112063831&v=2.20.1
Published: November 12, 2026 11:00
CONCLUSION: Adding oral glucocorticoids to ILD-modifying therapy was not associated with improved 12-month FVC in SSc-ILD. Secondary outcomes were sparse and should be interpreted cautiously.
Effects of adjunctive craniosacral therapy to conventional physiotherapy on postural responses and autonomic function in individuals with multiple sclerosis: a randomized controlled trial
https://pubmed.ncbi.nlm.nih.gov/43001615/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI&fc=None&ff=20261109135818&v=2.20.1
Published: November 9, 2026 11:00
CONCLUSION: CST added to conventional physiotherapy may influence specific postural response parameters in patients with MS. However, no between-group superiority was demonstrated, and no significant treatment effect on autonomic function was observed.…
Revisiting Daclizumab for Multiple Sclerosis: A Systematic Evaluation of a Targeted Immunotherapy
https://pubmed.ncbi.nlm.nih.gov/43000694/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI&fc=None&ff=20261109135818&v=2.20.1
Published: November 9, 2026 11:00
CONCLUSION: These findings suggest that Daclizumab may demonstrate promising treatment effects in MS patients by affecting the IL-2 receptor signaling pathway, modulating lymphocyte activity, and improving MS symptoms. However, because of documented…
Neuroinflammation in Alzheimer's disease: pathogenic signaling, biomarkers, and emerging therapeutic interventions
https://pubmed.ncbi.nlm.nih.gov/42996505/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI&fc=None&ff=20261108021247&v=2.20.1
Published: November 7, 2026 11:00
Alzheimer's disease (AD) is the leading cause of dementia worldwide, characterized by progressive cognitive decline and neurodegeneration. Although amyloid-β plaques and hyperphosphorylated tau are major pathological hallmarks, increasing evidence…
Phytocannabinoids in neurologic, neuropsychiatric, inflammatory, pain, cardiometabolic, hepatic, renal, and neoplastic disorders: Pharmacology, clinical evidence, and translational perspectives
https://pubmed.ncbi.nlm.nih.gov/42994510/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI&fc=None&ff=20261107001955&v=2.20.1
Published: November 6, 2026 11:00
Phytocannabinoids are pharmacologically diverse constituents of Cannabis sativa whose actions go beyond canonical cannabinoid receptors. Δ9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are best characterized, while cannabigerol, cannabidivarin,…
A two year clinical, immunological and gut-brain-axis prospective study to predict treatment response to cladribine tablets in relapsing-remitting multiple sclerosis
https://pubmed.ncbi.nlm.nih.gov/42985590/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI&fc=None&ff=20261105141857&v=2.20.1
Published: November 5, 2026 11:00
INTRODUCTION: In relapsing-remitting multiple sclerosis (RRMS) it is challenging to predict which person will benefit from a certain therapy, such as cladribine tablets (CladT). This study aimed to obtain a better understanding of the interaction between…
Multiple sclerosis relapse redefined: Effect of an MRI-supported relapse criterion on ublituximab outcomes in the ULTIMATE I and II trials
https://pubmed.ncbi.nlm.nih.gov/42978145/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI&fc=None&ff=20261104063021&v=2.20.1
Published: November 4, 2026 11:00
CONCLUSION: Requiring magnetic resonance imaging evidence substantially increases specificity of relapse ascertainment, unmasks treatment effects of high-efficacy therapy, and improves trial efficiency. Prospective validation of magnetic resonance…